Skip to content
OpenCapital
Get started

Acadia Pharmaceuticals ACAD Interest receivable on interest rate and cross currency swaps

Interest receivable on interest rate and cross currency swaps at other companies

Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
——

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M—
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0×0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InterestReceivableCurrent.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's interest receivable on interest rate and cross currency swaps.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's interest receivable on interest rate and cross currency swaps?
Acadia Pharmaceuticals (ACAD) reported interest receivable on interest rate and cross currency swaps of $13.03M in Q1 2026.
How has Acadia Pharmaceuticals's interest receivable on interest rate and cross currency swaps changed year-over-year?
Acadia Pharmaceuticals's interest receivable on interest rate and cross currency swaps increased by 63.5% year-over-year, from $7.97M to $13.03M.
What is the long-term trend for Acadia Pharmaceuticals's interest receivable on interest rate and cross currency swaps?
Over 5 years (2020 to 2025), Acadia Pharmaceuticals's interest receivable on interest rate and cross currency swaps has grown at a 67.4% compound annual growth rate (CAGR), from $2.04M to $26.77M.